Zetonna on the Market

The maker of Lunesta launched a new medication Zetonna, a dry, once-a-day nasal aerosol for allergies.  Approved by the  FDA in January the release to the public was delayed due to negotiations with the company’s partner, a company spokesperson said.Materials suggest Zetonna is appropriate for patients with either seasonal or perennial allergic rhinitis that are at least 12 years old.  The recommended dosage is one blast per nostril, per day.It is estimated that Allergic Rhinitis affects approximately 60 million people in the United States. Symptoms can include nasal stuffiness, runny nose, sneezing, itching, and breathing difficulty.  If you suffer from nasal allergies and live in the NYC area, call my office for a consultation.  There are solutions to ease your symptoms and improve the quality of your life.